Comprehensive Endometriosis Treatment in Ahmedabad, Under One Specialist Team

Medical therapy suppresses oestrogen-driven cyclical activity; it controls symptoms but does not eliminate disease, and suits pain control, disease suppression between fertility attempts, and patients in whom surgery is not currently indicated. Combined oral contraceptives (continuous) are first-line for pain in women not trying to conceive — continuous dosing eliminates withdrawal bleeding and is more effective than cyclical use, inexpensive and well tolerated. Progestins — dienogest 2 mg daily is highly effective and now preferred in many ESHRE pathways; the levonorgestrel intrauterine system (Mirena) provides excellent suppression with minimal systemic effect, especially valuable for adenomyosis and DIE-related dysmenorrhoea. GnRH analogues with add-back are reserved for severe disease unresponsive to first-line therapy, always paired with low-dose add-back to protect bone density, typically limited to six months, and useful pre-surgically or as a bridge to IVF. Importantly, medical therapy is contraceptive — it cannot be used while actively trying to conceive, does not reverse anatomical distortion, and does not restore ovarian reserve.

Surgery has a clear evidence base, but only for the right indications and by a surgeon trained in advanced laparoscopic excision. Done poorly, repeated surgery causes more harm than the disease itself — ovarian-reserve loss, dense adhesions, recurrent pain and lost fertility opportunities. Surgery is appropriate for severe pain not controlled by adequate medical therapy; an endometrioma over 3–4 cm causing pain, growth or interfering with IVF stimulation; deep infiltrating disease with bowel, bladder or ureteric involvement; mechanical infertility; suspected malignancy; or diagnostic uncertainty after a thorough non-invasive workup. Current evidence (Cochrane reviews, ESHRE 2022, AAGL) supports excision over ablation for deep and ovarian disease — better pain outcomes, lower recurrence and more accurate histology.

Every endometriosis surgery in a woman with fertility goals follows strict ovarian-sparing principles: pre-operative AMH and antral follicle count documented; endometrioma cystectomy by stripping technique with minimal cautery near the hilum and suturing preferred for haemostasis; avoiding repeat surgery on the same ovary wherever possible; discussing cumulative ovarian-reserve impact before consent; and considering oocyte or embryo cryopreservation before surgery in selected cases. Deep infiltrating endometriosis — ureteric dissection, rectovaginal septum work, bowel shaving or discoid/segmental resection — must be performed in a centre with multidisciplinary colorectal and urology support.

Endometriosis is chronic; the goal is not "cure" but durable control with the minimum cumulative intervention. Recurrence after surgery alone ranges 20–50% over five years depending on phenotype and post-surgical hormonal suppression — with appropriate maintenance (continuous OCP, dienogest or LNG-IUS) recurrence and reoperation are meaningfully reduced. Long-term care includes annual clinical and ultrasound review to track disease, ovarian reserve and symptom trajectory; anti-inflammatory dietary pattern, pelvic physiotherapy, regular aerobic exercise, sleep regulation and stress management as modest adjuncts; formal psychological support for the burden of chronic pelvic pain; early fertility-window planning rather than deferring until reserve is already low; and nuanced, individualised hormone-therapy decisions through the menopause transition, when most disease activity diminishes but symptoms can persist.

Endometriosis reduces fertility through multiple converging mechanisms, each calling for a different intervention: adhesions distort tubo-ovarian anatomy and impair egg pickup; endometriomas independently lower AMH and antral follicle count even before surgery; an inflammatory peritoneal milieu of cytokines and oxidative stress impairs sperm function, fertilisation and early embryo development; altered HOXA-10 expression and progesterone resistance reduce endometrial receptivity and implantation even with good embryos; reactive oxygen species in follicular fluid affect oocyte mitochondrial health; and coexisting adenomyosis impairs uterine peristalsis and implantation — a frequently missed contributor to "unexplained" IVF failure. Fertility planning is therefore individualised: a 28-year-old with mild disease, regular ovulation and normal AMH has very different options from a 36-year-old with bilateral endometriomas, AMH 1.2 ng/mL and a partner with mild male factor.